Dr. Hilary Cass

The assessment of studies looks at things like, do they follow up for long enough? Do they lose a lot of patients during the follow-up period? Do they have good comparison groups? And the reason the studies are weak is because they failed on one or more of those areas that I've just described.

The assessment of studies looks at things like, do they follow up for long enough? Do they lose a lot of patients during the follow-up period? Do they have good comparison groups? And the reason the studies are weak is because they failed on one or more of those areas that I've just described.

The Dutch team picked the first 70 people who were ready to go on to the next stage, so they were in some ways picking the people who, you know, done best on the puberty blockers.

The Dutch team picked the first 70 people who were ready to go on to the next stage, so they were in some ways picking the people who, you know, done best on the puberty blockers.

Publishing negative results is really important. And so that perpetuated, because they went on to routinely prescribing, people might have assumed that they'd got positive results. So failure to publish is a problem again.

Publishing negative results is really important. And so that perpetuated, because they went on to routinely prescribing, people might have assumed that they'd got positive results. So failure to publish is a problem again.

The group of young people presenting now who are predominantly birth-registered girls presenting in teenage years are very different from the original group of young people who are predominantly birth-registered boys presenting from early childhood. And so even the research that we have, weak as it is, was mainly about that other group.

The group of young people presenting now who are predominantly birth-registered girls presenting in teenage years are very different from the original group of young people who are predominantly birth-registered boys presenting from early childhood. And so even the research that we have, weak as it is, was mainly about that other group.

And it doesn't tell us the best way to manage this newer presenting group.

And it doesn't tell us the best way to manage this newer presenting group.

Yeah, it has been treated differently up till now. So the University of York, which is kind of the home of systematic reviews, one of the key organisations that does them in this country, just found it was strikingly lower than other areas, even in paediatrics.

Yeah, it has been treated differently up till now. So the University of York, which is kind of the home of systematic reviews, one of the key organisations that does them in this country, just found it was strikingly lower than other areas, even in paediatrics.

I think what's unique for me is that if we do give a potentially life-changing treatment to a young person and we don't have good evidence about it, then the responsible thing to do is that you must follow them up into adulthood. And really, I can't think of any other situation where we do give life-altering treatments and we just don't have enough understanding about what's happening there.

I think what's unique for me is that if we do give a potentially life-changing treatment to a young person and we don't have good evidence about it, then the responsible thing to do is that you must follow them up into adulthood. And really, I can't think of any other situation where we do give life-altering treatments and we just don't have enough understanding about what's happening there.

to those young people in adulthood.

to those young people in adulthood.

Yeah. So I have spoken to very many clinicians in the US, in Europe and in the UK who also have many years experience and have come to a different conclusion. So you have both clinical perspectives. And that's why in the end, you can't just rely on your clinical experience. And I think

Yeah. So I have spoken to very many clinicians in the US, in Europe and in the UK who also have many years experience and have come to a different conclusion. So you have both clinical perspectives. And that's why in the end, you can't just rely on your clinical experience. And I think

Certainly, I've spoken to young adults who are clearly thriving for, you know, a medical pathway has been the right thing for them. And I've also spoken to young adults where it was the wrong decision, where they have regret, where they've detransitioned. And the critical issue is trying to work out how we can best predict who's going to thrive and who is not going to do well in

Certainly, I've spoken to young adults who are clearly thriving for, you know, a medical pathway has been the right thing for them. And I've also spoken to young adults where it was the wrong decision, where they have regret, where they've detransitioned. And the critical issue is trying to work out how we can best predict who's going to thrive and who is not going to do well in